ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation
Full article:

The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)

Este artículo está disponible en español.

Questions To Ask Your Health Care Provider

Open Clinical Trials


FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.